Credit Suisse Ag Immuno Gen, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$12.46 - $29.95 $1.55 Million - $3.72 Million	124,236 Added 42.4%	417,277 $12.4 Million
Q3 2023 Nov 13, 2023	SELL	$14.09 - $19.87 $347,713 - $490,351	-24,678 Reduced 7.77%	293,041 $4.65 Million
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $121,252 - $648,296	32,334 Added 11.33%	317,719 $6 Million
Q1 2023 May 10, 2023	SELL	$3.67 - $4.92 $17,322 - $23,222	-4,720 Reduced 1.63%	285,385 $1.1 Million
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $56,583 - $78,471	12,436 Added 4.48%	290,105 $1.44 Million
Q3 2022 Nov 10, 2022	BUY	$4.48 - $6.47 $92,395 - $133,437	20,624 Added 8.02%	277,669 $1.33 Million
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $38,445 - $70,300	-12,205 Reduced 4.53%	257,045 $1.16 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $18,590 - $32,642	4,364 Added 1.65%	269,250 $1.28 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $66,333 - $104,737	13,965 Added 5.57%	264,886 $1.97 Million
Q3 2021 Nov 12, 2021	BUY	$5.02 - $6.59 $51,364 - $67,428	10,232 Added 4.25%	250,921 $1.42 Million
Q2 2021 Aug 16, 2021	SELL	$5.79 - $8.6 $80,289 - $119,256	-13,867 Reduced 5.45%	240,689 $1.59 Million
Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $746,739 - $1.21 Million	-114,883 Reduced 31.1%	254,556 $2.06 Million
Q4 2020 Feb 12, 2021	BUY	$3.7 - $7.66 $21,907 - $45,354	5,921 Added 1.63%	369,439 $2.38 Million
Q3 2020 Nov 13, 2020	SELL	$3.45 - $4.89 $163,547 - $231,810	-47,405 Reduced 11.54%	363,518 $1.31 Million
Q2 2020 Aug 12, 2020	BUY	$3.32 - $5.34 $1.02 Million - $1.64 Million	306,288 Added 292.72%	410,923 $1.89 Million
Q1 2020 May 13, 2020	SELL	$2.12 - $6.8 $19,037 - $61,064	-8,980 Reduced 7.9%	104,635 $357,000
Q4 2019 Feb 12, 2020	BUY	$2.25 - $5.8 $31,891 - $82,209	14,174 Added 14.25%	113,615 $580,000
Q3 2019 Nov 12, 2019	BUY	$2.22 - $3.39 $30,502 - $46,578	13,740 Added 16.03%	99,441 $240,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $75,767 - $138,906	-42,093 Reduced 32.94%	85,701 $186,000
Q1 2019 May 14, 2019	BUY	$2.41 - $5.91 $6,678 - $16,376	2,771 Added 2.22%	127,794 $346,000
Q4 2018 Feb 13, 2019	SELL	$3.94 - $9.7 $76,471 - $188,267	-19,409 Reduced 13.44%	125,023 $601,000
Q3 2018 Nov 13, 2018	SELL	$8.6 - $11.26 $390,457 - $511,226	-45,402 Reduced 23.92%	144,432 $1.37 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $539,546 - $688,601	56,675 Added 42.56%	189,834 $1.85 Million
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $35,952 - $69,489	5,366 Added 4.2%	133,159 $1.4 Million
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $79,315 - $123,900	-15,644 Reduced 10.91%	127,793 $818,000
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $78,062 - $122,442	14,456 Added 11.21%	143,437 $1.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	128,981	128,981 $917,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account